Long-Term Water Vapor Thermal Therapy Outcomes Across a Broad Range of Prostate Volumes
- 1 July 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 11 (4) , 727-734
Abstract
Water vapor thermal therapy (WVTT) is a minimally invasive therapy designed to treat lower urinary tract symptoms associated with benign prostatic hyperplasia. Long-term outcomes with large (>80 cc) and small ( 80 cc. Outcome measures, including International Prostate Symptom Score, quality of life, International Index of Erectile Function, medication usage, and adverse events, were analyzed at baseline and at 1-, 3-, 6-, 12-, 24-, 36-, and/or 48-month follow-up. Two hundred fifty-two patients met inclusion; 35 (13.9%) had PVs < 30 cc, 196 (77.8%) had PVs 30 to 80 cc, and 21 (8.3%) had PVs > 80 cc. Most patients were Asian (33.7%) or non-Hispanic Black (29.4%). International Prostate Symptom Score and quality of life improved in all cohorts from baseline at all follow-ups (all P < .05), with no differences between cohorts. International Index of Erectile Function-Orgasmic Function and -Erectile Function domains improved in 30 to 80 cc patients at 48 months. Alpha blocker and/or 5-alpha reductase inhibitor usage decreased at all follow-ups in < 30 cc and 30 to 80 cc patients and remained durable to only 6 months for > 80 cc patients. No significant differences in adverse events or reoperation rates were observed between cohorts. Our study suggests WVTT to be efficacious, durable, and safe in managing lower urinary tract symptoms across PVs, although PV > 80 cc patients may require benign prostatic hyperplasia medication at long-term follow-up. Further research is desired to clarify WVTT's role regarding sexual function and in treating men with larger PVs.Keywords
This publication has 37 references indexed in Scilit:
- Prospective Trial of Water Vapor Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia in Subjects with a Large Prostate: 6- and 12-month OutcomesEuropean Urology Open Science, 2023
- Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract SymptomsEuropean Urology, 2023
- Rezum water vapor therapy for patients with mild, moderate, or severe lower urinary tract symptoms: A retrospective study in a multiethnic populationThe Prostate, 2023
- Real‐world evidence with The Rezūm System: A retrospective study and comparative analysis on the efficacy and safety of 12 month outcomes across a broad range of prostate volumesThe Prostate, 2021
- Rezum therapy for patients with large prostates (≥ 80 g): initial clinical experience and postoperative outcomesWorld Journal of Urology, 2021
- Treatment of benign prostate hyperplasia using the Rezum® water vapor therapy system: Results at one yearProgrès en Urologie, 2020
- Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE TrialEuropean Urology, 2016
- National Trends of Simple Prostatectomy for Benign Prostatic Hyperplasia With an Analysis of Risk Factors for Adverse Perioperative OutcomesUrology, 2015
- Prevalence and Characteristics of Lower Urinary Tract Symptoms in Men Aged ≥80 YearsUrology, 2008
- Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: The MrOS studyUrology, 2006